ArticleThe CRISPR journal2023

Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies.

Guillermo Ureña-Bailén et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.